Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
The Pharma Data
SEPTEMBER 15, 2020
Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. “When Amgen first partnered with us in 2015, MBC BioLabs was a single site in San Francisco hosting 40 companies.
Let's personalize your content